ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

By Peter Loftus Of DOW JONES NEWSWIRES Drug maker Bristol-Myers Squibb Co. (BMY) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas. Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries." The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing. Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA. U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement. Last year, Johnson & Johnson (JNJ) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein. Other drug makers--including Pfizer Inc. (PFE), Merck & Co. (MRK) and Eli Lilly & Co. (LLY)--also have been the subjects of federal inquiries regarding the FCPA. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
02/10/201613:34:00Correction to Merck & Co. Article on Jan. 15
02/10/201610:28:27Amended Statement of Ownership (sc 13g/a)
02/10/201608:50:59Amended Statement of Ownership (sc 13g/a)
02/04/201608:00:00FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) fo...
02/03/201616:13:00Merck Posts Lower Revenue and Profit -- 2nd Update
02/03/201616:09:00Correction to Merck Earnings Story
02/03/201613:08:00Merck Revenue and Profit Falls -- Update
02/03/201608:30:00Merck Revenue and Profit Falls
02/03/201608:21:00Merck Revenue and Profit Falls
02/03/201606:57:37Current Report Filing (8-k)
02/03/201606:45:00Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
01/28/201621:36:00FDA Approves Merck's New Hepatitis C Treatment -- 2nd Update
01/28/201620:15:00FDA Approves Merck's New Hepatitis C Treatment -- Update
01/28/201619:10:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) f...
01/28/201618:59:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir & grazoprevir) f...
01/27/201613:49:00FDA to Review Merck Antitoxin for Clostridium Difficile
01/27/201608:30:00Merck Announces FDA Acceptance of Biologics License Application...
01/25/201605:00:00Affimed Enters into Collaboration with Merck to Evaluate AFM13...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad